The Ecological Role of Yeasts in the Human Gut

Assessing the Ecological Role of Yeasts in the Human Gut and Their Impact on Gastrointestinal Disorders

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04138225

Acronym

YIG

Enrollment

120

Registered

2019-10-24

Start date

2018-09-23

Completion date

2021-09-23

Last updated

2019-10-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastrointestinal Disease, Inflammatory Bowel Diseases, Irritable Bowel Syndrome

Keywords

yeast, mycology, gut, microbiota, gastrointestinal disorders

Brief summary

Irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD) (categorised into Crohn's disease (CD) and ulcerative colitis (UC)) are chronic gut disorders with debilitating symptoms that profoundly impact quality of life, healthcare systems and the economy through lost work days. IBS is common with a prevalence of up to 22%, whereas IBD has a prevalence of 0.3% for CD and 0.5% for UC in Europe. Despite a suggested immunological and genetic aspect of IBD, the causes of IBS and IBD are unknown, however, both have been linked to yeasts in the gut. Due to their lower abundance (constituting only around 0.1% of the total microorganisms in the gut) yeasts have been less studied than bacteria. More recently, significantly altered diversity and composition of yeasts have been identified in IBS and IBD but further investigation is required to fully develop the role of yeasts in the gut. This observational study will assess yeasts and their function in the gut, comparing diseased subjects with healthy controls. The overall aim is to determine if yeasts could be targeted as a potential therapeutic for IBS and IBD to provide relief to sufferers as well as reducing the burden on healthcare systems.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

OTHER

Eligibility

Sex/Gender

ALL

Age

20 Years to 60 Years

Healthy volunteers

Yes

Inclusion criteria

* Aged 20-60 years old. * Either healthy or diagnosed with a gut disorder: Irritable Bowel Syndrome (IBS) or Inflammatory Bowel Disease (IBD) which may include Crohn's disease or ulcerative colitis. * In good general health. * Provided written informed consent and willing to participate in this study.

Exclusion criteria

* Received antibiotics in the previous six months. * Consume prebiotics or probiotics on a regular basis (at least 3 times per week) in the last 2 weeks or intend to throughout the course of the study. (Examples of these include: Multibionta multivitamins, Danone Actimel yoghurt drink; Danone Activia yoghurt; Yakult fermented milk drink; Kellogg's Rice Krispies multigrain and Muller Vitality yoghurts/drinks). * Current use of immunosuppressive drugs. * Use of other medication which affects gastrointestinal motility and/or gut discomfort. * History of alcohol or drug misuse.

Design outcomes

Primary

Measure	Time frame	Description
Yeast species in gut	Baseline	Measured from stool samples using fluorescence in situ hybridisation
Metabolic profile	Baseline	Measures from stool, urine and blood samples using nuclear magnetic resonance spectroscopy

Secondary

Measure	Time frame	Description
Calprotectin	Baseline	Measured using ELISA
Lactorferrin	Baseline	Measured using ELISA

Countries

United Kingdom

Contacts

Primary ContactGrace Newland, MSc

grace.ward@pgr.reading.ac.uk07956783096

Outcome results